The use of the glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention

Journal of Interventional Cardiology

Volumn 15, Issue 1, 2002, Pages 71-84

  Marmur, Jonathan D ^a   Cavusoglu, Erdal ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST;

CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; DRUG USE; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; TREATMENT INDICATION;

EID: 0036118649     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2002.tb01036.x     Document Type: Review

References (57)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes (1)
2. Glycoprotein IIb/IIIa inhibitors: Current indications and future prospects
3. Recognition of the importance of embolization in atherosclerotic vascular disease
4. Shifting the open-artery hypothesis downstream: The quest for optimal reperfusion
5. Influence of a platelet GP IIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy
6. Prognostic implication of creatine kinase elevation following elective coronary artery interventions
7. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
8. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
9. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
10. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
11. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
12. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II
13. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial
14. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
15. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
16. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
17. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization
18. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
19. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
20. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention
21. Role of platelet inhibitor agents in coronary artery disease
22. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
23. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicenter randomized trial
24. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial
25. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE)
26. IIbs are not IIb's
27. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
28. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris
29. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
30. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose Integrelin in coronary intervention: Results of the PRIDE study
31. Eptifibatide pharmacokinetic-pharmacodynamic relationship in coronary angioplasty patients: Results of the PRIDE study
32. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial
33. Consistent and durable reduction in death and myocardial infarction with abciximab during coronary intervention in acute coronary syndromes and unstable angina
34. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels
35. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
36. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty
37. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty
38. Targeting patients undergoing angioplasty for thrombus inhibition: A cost-effectiveness and decision support model
39. Coronary artery stents: Gauging, gorging, and gouging
40. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease
41. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
42. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology
43. The benefit of abciximab in percutaneous coronary revascularization is not device-specific
44. Abciximab provides cost-effective survival advantage in high-volume interventional practice
45. Abciximab: Cost-effective survival advantage in clinical trials and clinical practice
46. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?
47. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
48. Glycoprotein IIb/IIIa integrin blockade
49. Glycoprotein IIb/IIIa Inhibitors: More different than alike?
50. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
51. Current use of IIb/IIIa receptor antagonists during coronary intervention: The NHLBI 1997-1998 dynamic registry
52. Economic issues in glycoprotein IIb/IIIa receptor therapy
53. Calming the plaque to delay intervention for 24 hours in acute coronary syndromes
54. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms)
55. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization
56. Antithrombotic therapy in patients with acute coronary syndromes
57. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention